Recombinant Human ANXA1 Protein

Name: Recombinant Human ANXA1 Protein
Brand: Beta LifeScience
SKU: BL-1797NP
Availability: InStock

BL-1797NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Annexin A1 is produced by our E.coli expression system and the target gene encoding Ala2-Asn346 is expressed.
Accession	P04083
Synonym	Annexin A1; Annexin I; Annexin-1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; Phospholipase A2 Inhibitory Protein; p35
Gene Background	Annexin A1 is the first characterized member of the annexin family of proteins and is able to bind to cellular membranes in a calcium-dependent manner, promoting membrane fusion and endocytosis. Annexin A1 has anti-inflammatory properties and inhibits phospholipase A2 activity. Annexin A1 also has roles in many diverse cellular functions, such as membrane aggregation, inflammation, phagocytosis, proliferation, apoptosis, and tumorigenesis and cancer development. ANXA1 is strongly expressed on the cell membrane and occasionally in the cytoplasm of tumor cells in 97% of samples from patients with hairy cell leukemia.
Molecular Mass	38.58 KDa
Apmol Mass	34 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity. Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response. Promotes resolution of inflammation and wound healing. Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades. Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors. Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells. Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells. Has no effect on unstimulated T cells. Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration. Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton. Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions. Displays Ca(2+)-dependent binding to phospholipid membranes. Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton.
Subcellular Location	Nucleus. Cytoplasm. Cell projection, cilium. Cell membrane. Membrane; Peripheral membrane protein. Endosome membrane; Peripheral membrane protein. Basolateral cell membrane. Apical cell membrane. Lateral cell membrane. Secreted. Secreted, extracellular space. Cell membrane; Peripheral membrane protein; Extracellular side. Secreted, extracellular exosome. Cytoplasmic vesicle, secretory vesicle lumen. Cell projection, phagocytic cup. Early endosome. Cytoplasmic vesicle membrane; Peripheral membrane protein.
Protein Families	Annexin family
Database References	HGNC: 533 OMIM: 151690 KEGG: hsa:301 STRING: 9606.ENSP00000257497 UniGene: PMID: 29932988 These results could lead to further information on ANXA1 intracellular role in pancreatic cancer , explaining other aspects that are apart from its tumorigenic behaviour. PMID: 29986379 There was an inverse correlation between the expressions of miR-196a and ANXA1 in serum (Pearson's correlation of -0.54, P = 0.021). Our data revealed that the expression of serum ANXA1 in esophageal squamous cell carcinoma (ESCC) patients increases after chemoradiotherapy and the increased fold change in serum ANXA1 confers independent negative prognostic impact in ESCC. PMID: 30249885 the results highlighted the protective effects of ANXA1 on bronchial epithelium injury, which most likely occurred via the PTEN/FAK/PI3K/Akt signaling pathway. Thus, the present study contributes to a potential therapeutic strategy for asthma patients. PMID: 29749523 Enhanced levels of Annexin A1 were found in the serum and adipose tissue of individuals with obesity and type 2 diabetes mellitus. PMID: 29677533 Annexin A1 expression is upregulated in patients with COPD and affects lung fibroblast function. PMID: 29440885 that the actions of ANXA1 in the inflammatory and neoplastic processes of the esophagus and stomach are specifically mediated by the formylated peptides receptor 1 PMID: 29254791 Annexin A1 has a similar immunogenic expression and correlation with its analog Annexin A2 and their association may be a novel immune target of BD in Han Chinese population PMID: 28963375 We further identified this underlying mechanism also involved a PPARgamma-induced ANXA1-dependent autoubiquitination of cIAP1, the direct E3 ligase of RIP1, shifting cIAP1 toward proteosomal degradation..our study provides first insight for the suitability of using drug-induced expression of ANXA1 as a new player in RIP1-induced death machinery in triple-negative breast cancer PMID: 29021293 this review details the therapeutic relevance of ANXA1 and its derived peptides in cardiovascular diseases since atherosclerosis stands out as a chronic inflammatory disease with impaired resolution and continuous leukocyte recruitment. PMID: 27860536 Our results indicated that ANXA1 may be a key mediator of hypoxia-related metastasis-associated processes in prostate cancer PMID: 27834582 Data indicate a regulatory circuit between ANXA1, NF-kB, c-myc and miR-196a which regulates breast cancer cell proliferation and tumor growth. PMID: 27105503 In colorectal cancer, miR-196a over-expression was negatively correlated with annexin A1 protein expression (r = -0.738, p < 0.001), and both were indicators of unfavorable prognosis in terms of poor differentiation, larger tumor size, and advanced clinical stage PMID: 29091952 The data of this study supported a potential role of ANXAl in AD by reducing Abeta levels and decreasing neuroinflammation, suggesting a novel view that ANXAl may play a protective role in AD progression. PMID: 27590054 these data indicate that AnxA1 is actively expressed during L. braziliensis infection. PMID: 28289158 Data, including data from studies using knockout mice, suggest cAMP-elevating agents increase levels of ANXA1; this is involved in role of cAMP in resolving acute inflammation (here, ability of cAMP-elevating agents to treat LPS-induced neutrophilic pleurisy). These results reinforce hypothesis that ANXA1 acts in multiple cell types (neutrophils, macrophages) and at multiple levels to promote resolution of inflammation. PMID: 28655761 Circulating IgG antibodies to ANXA1 could be used as a biomarker for early diagnosis of non-small cell lung carcinoma. PMID: 28551657 Down-regulation of Annexin A1 in nasopharyngeal carcinoma may lead to the overexpression of S100A9/Vimentin, which may increase the possibility of the invasion ability of NPC cells by adjusting the function of cytoskeleton proteins. PMID: 28355254 ANXA1 is down-regulated and differentially expressed within the SCD genotypes PMID: 27802331 Annexin A1-regulated contacts function in the transfer of endoplasmic reticulum-derived cholesterol to the multivesicular endosomes/bodies when low-density lipoprotein-cholesterol in endosomes is low. PMID: 27270042 This review explores the diverse actions of annexin A1 on breast tumor cells and various host cell types, including stromal immune and structural cells, particularly in the context of cancer immunoediting. [annexin A1] PMID: 28212890 ANXA1 restores Abeta42-induced blood brain barrier disruption through inhibition of RhoA-ROCK signaling pathway PMID: 27633771 High ANXA1 expression is associated with lymphatic invasion and malignant progression of lung cancer. PMID: 28009433 Annexin A1 role in colon cancer cells drug resistance to 5-fluorouracil PMID: 27840982 ANXA1 promotes the proliferation of Eca109 cells, and increases the expression of Snail, whereas it inhibits that of E-cadherin, thus enhancing the migration and invasion of ESCC cells. miRNA-196a negatively regulates the expression of ANXA1 PMID: 28035369 the present study provided evidence suggesting that ANXA1 may contribute to the growth and invasion of NSCLC cell lines PMID: 27035116 Simultaneous knock-down of HIF-1alpha and Annexin A1 (ANXA1), one of the identified genes, resulted in complete cessation of proliferation of gastric cancer. PMID: 26760764 ANXA1 and CALD1 proteins are independent markers for tamoxifen therapy outcome and are associated to fast tumor progression. PMID: 26657294 High ANXA1 expression is associated with Colorectal Cancer. PMID: 26687139 Results show that ANXA1 and ANXA10 are highly expressed in pancreatic ductal adenocarcinoma and its metastases to the liver comparing to intrahepatic cholangiocellular carcinoma. PMID: 26644413 We conclude that ANX-A1 is an important regulator of mast cell reactivity to compound 48/80 exerting a negative feedback effect through a mechanism that depends at least partly on the FPR receptor PMID: 26803520 AnxA1 and its mimetic peptides inhibit neutrophil tissue accumulation by reducing leukocyte infiltration and activating neutrophil apoptosis. PMID: 26885535 results suggest that overexpression of CRISP-3 in prostate tumor may maintain higher PSA expression and lower ANXA1 expression PMID: 26369530 Data show that high density lipoprotein (HDL) up-regulated expression of annexin A1 (ANXA1) in HUVEC vascular endothelial cells in a dose-dependent (Fig. 1A-B) and time-dependent manners. PMID: 27012521 Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. PMID: 26312765 increased AnxA1 levels were associated with a systemic inflammatory phenotype in preeclampsia. PMID: 26398190 Data show that elevated levels of annexin A1 are associated with small cell lung cancer {SCLC) brain metastasis. PMID: 26135980 Within the basal subtype of breast cancer, patients show significantly poorer overall survival associated with higher expression of annexin A1. PMID: 26000884 ANXA1 negatively regulated the step of viral RNA replication rather than that of viral entry in human hepatocytes. PMID: 25899628 Loss of ANXA1 is associated with lymphatic metastasis in pancreatic ductal adenocarcinoma. PMID: 25854353 ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. PMID: 26137966 Cardioprotective potential of annexin-A1 mimetics in myocardial infarction PMID: 25460034 data indicate the involvement of ANXA1Ac2-26 in the altered expression of genes involved in tumorigenic processes, which could potentially be applied as a therapeutic indicator of cervical cancer PMID: 26072160 These results suggested that ANXA1, which enhanced breast cancer invasion and metastasis under hypoxia, were significantly associated with the worst patient outcome in triple-negative breast cancer PMID: 25592491 Increased expression of ANXA1 protein associates with aggressive progression and poor prognosis in hepatocellular carcinoma patients. PMID: 25412936 Overexpression of ANXA1 induced by low-concentration Arsenic Trioxide (ATO) makes cancer cells more resistant to the agent via activated ERK MAPKs. Specific silencing of ANXA1 increased the sensitivity of cancer cells to ATO treatment. PMID: 25983101 ANXA1 may contribute to the regulation of tumor growth and metastasis through paracrine mechanisms that are mediated by FPR2/ALX PMID: 25490767 the co-upregulated expression of mast cell chymase and ANXA1-FPR1 system in ectopic endometrium suggests their involvement in the development of endometriotic lesions. PMID: 25201101 This data suggests that ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-kappaB expression and point towards a potential therapeutic target for breast cancer. PMID: 25536365 Study provides new insights on the role of ANXA1 protein in pancreatic cancer progression and suggest that ANXA1 protein could regulate metastasis by favouring cell migration/invasion. PMID: 25510623

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.